Hirudo Lyophilized Powder Ameliorates Renal Injury in Diabetic Rats by Suppressing Oxidative Stress and Inflammation
Table 2
Clinical parameters of different groups.
Parameters
C group
DM group
SL group
SM group
SH group
KW/BW (g/100g)
0.28 ± 0.04
0.59 ± 0.04
0.47 ± 0.09##
0.41 ± 0.05##
0.39 ± 0.04##
SCr (μmol/L)
24.36 ± 2.70
50.10 ± 4.11
43.80 ± 5.89#
38.03 ± 5.83##
31.49 ± 5.90##
BUN (mmol/L)
7.82 ± 0.82
16.05 ± 0.70
13.95 ± 1.77##
12.05 ± 1.54##
10.07 ± 1.35##
24 h-UTP (mg/d)
5.76 ± 1.54
42.44 ± 5.93
34.79 ± 5.29##
29.13 ± 4.96##
25.83 ± 5.91##
CHO (mmol/L)
2.72 ± 0.29
6.00 ± 0.75
5.48 ± 0.63
4.20 ± 0.51##
3.54 ± 0.35##
TG (mmol/L)
1.09 ± 0.08
3.72 ± 0.56
2.70 ± 0.19##
2.07 ± 0.18##
1.54 ± 0.25##
The SL, SM, and SH group rats were dosed by oral gavage once daily for 16 weeks with Hirudo lyophilized powder. The C and DM group rats were administered the same volume of vehicle used to prepare the test medications. Data are presented as means ± SD (n = 7 in DM and SL groups, n = 8 in the other groups). < 0.01 vs. C group; # < 0.05 and ## < 0.01 vs. DM group.
